Full List of Cannabidiol Research, Notable Studies on CBD and Current Clinical CBD Trials

Notable Studies on CBD for Anxiety:

• Neural Basis of Anxiolytic Effects of Cannabidiol (CBD) in Generalized Social Anxiety Disorder: a Preliminary Report
• 
  Antidepressant-like and Anxiolytic-like Effects of Cannabidiol: a Chemical Compound of Cannabis Sativa
  
• 
  Cannabidiol as a Potential Treatment for Anxiety Disorders
  
• 
  Cannabidiol, a Cannabis Sativa Constituent, as an Anxiolytic Drug
  
• 
  Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-naive Social Phobia Patients
  
• 
  Central Anandamide Deficiency Predicts Stress-induced Anxiety: Behavioral Reversal Through Endocannabinoid Augmentation
  
• 
  The Anxiolytic Effect of Cannabidiol on Chronically Stressed Mice Depends on Hippocampal Neurogenesis: Involvement of the Endocannabinoid System
  
• 
  Cannabidiol Regulation of Emotion and Emotional Memory Processing: Relevance for Treating Anxiety-related and Substance Abuse Disorders
  
• 
  Effects of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report
  
• 
  Effect of Prior Foot Shock Stress and Delta9-Tetrahydrocannabinol, Cannabidiolic Acid, and Cannabidiol on Anxiety-like Responding in the Light-dark Emergence Test in Rats
  
• 
  A Systematic Review of Plant-Derived Natural Compounds for Anxiety Disorders
  
• 
  Plant-based Medicines for Anxiety Disorders, Part 2: a Review of Clinical Studies With Supporting Preclinical Evidence
  
• 
  Cannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults

Notable Studies on Cannabidiol for Psychosis:

• 
  Cannabis Drug Shows Promise in Treating Schizophrenia
  
• 
  Cannabidiol, a Cannabis Sativa Constituent, as an Antipsychotic Drug
  
• 
  Cannabidiol as a Potential Treatment for Psychosis
  
• 
  Medical use of Cannabis. Cannabidiol: a New Light for Schizophrenia?
  
• 
  Cannabinoids and Schizophrenia: Therapeutic Prospects
  
• 
  Cannabidiol Monotherapy for Treatment-Resistant Schizophrenia
  
• Marijuana Compound Treats Schizophrenia with Fewer Side Effects: Clinical Trial
• 
  Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model
  
• 
  Cannabidiol Enhances Anandamide Signaling and Alleviates Psychotic Symptoms of Schizophrenia
  
• 
  A Critical Review of the Antipsychotic Effects of Cannabidiol: 30 Years of Translational Investigation
  
• 
  Cannabis with High Cannabidiol Content is Associated with Fewer Psychotic Experiences
  
• 
  Neuronal and Molecular Effects of Cannabidiol on the Mesolimbic Dopamine System: Implications for Novel Schizophrenia Treatments
  
• 
  Antipsychotic-like Effects of Cannabidiol and Rimonabant: Systematic Review of Animal Studies
  
• 
  Clearing the Smoke: What do We Know About Adolescent Cannabis Use and Schizophrenia?
  
• 
  Peripheral Endocannabinoid System Dysregulation in First-episode Psychosis
  
• Study: Cannabidiol Holds Promise for Treating Psychosis
• 
  The Yin and Yang of Cannabis-induced Psychosis: the Actions of Delta9-Tetrahydrocannabinol and Cannabidiol in Rodent Models of Schizophrenia
  
• 
  Potential Protective Effects of Cannabidiol on Neuroanatomical Alterations in Cannabis Users and Psychosis: a Critical Review
  

Notable Studies on Cannabidiol for Arthritis:

• 
  Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress
  
• 
  Therapeutic Potential of Cannabinoid-based Drugs
  
• 
  Oral Anti-inflammatory Activity of Cannabidiol, a Non-psychoactive Constituent of Cannabis, in Acute Carrageenan-induced Inflammation in the Rat Paw
  
• 
  The Abnormal Cannabidiol Analogue O-1602 Reduces Nociception in a Rat Model of Acute Arthritis Via the Putative Cannabinoid Receptor GPR55
  
• Preliminary Assessment of the Efficacy, Tolerability and Safety of a Cannabis-based Medicine (Sativex) in the Treatment of Pain Caused by Rheumatoid Arthritis
• The Nonpsychoactive Cannabis Constituent Cannabidiol Is an Oral Anti-arthritic Therapeutic in Murine Collagen-induced Arthritis
• 
  Involvement of the Endocannabinoid System in Osteoarthritis Pain
  
• 
  Attenuation of Early Phase Inflammation by Cannabidiol Prevents Pain and Nerve Damage in Rat Osteoarthritis
  

Notable Studies on Cannabidiol for Cancer:

• 
  Inhibition of Colon Carcinogenesis by a Standardized Cannabis Sativa Extract With High Content of Cannabidiol
  
• 
  Cannabidiol, a Non-psychoactive Cannabinoid Compound, Inhibits Proliferation and Invasion in U87-MG and T98G Glioma Cells Through a Multitarget Effect
  
• 
  Gamma-irradiation Enhances Apoptosis Induced by Cannabidiol, a Non-psychotropic Cannabinoid, in Cultured Hl-60 Myeloblastic Leukemia Cells
  
• 
  Cannabidiol as a Novel Inhibitor of Id-1 Gene Expression in Aggressive Breast Cancer Cells
  
• 
  Cannabidiol Induces Programmed Cell Death in Breast Cancer Cells by Coordinating the Cross-talk between Apoptosis and Autophagy
  
• 
  Cannabinoids for Cancer Treatment: Progress and Promise
  
• Antitumor Activity of Plant Cannabinoids with Emphasis on the Effect of Cannabidiol on Human Breast Carcinoma
• 
  Cannabidiol Inhibits Growth and Induces Programmed Cell Death in Kaposi Sarcoma-associated Herpesvirus-infected Endothelium
  
• Cannabidiol-Induced Apoptosis in Human Leukemia Cells: A Novel Role of Cannabidiol in the Regulation of p22phox and Nox4 Expression
• Triggering of the Trpv2 Channel by Cannabidiol Sensitizes Glioblastoma Cells to Cytotoxic Chemotherapeutic Agents
• 
  Cannabis and Cannabinoids (PDQ®)–Health Professional Version
  
• 
  Cannabidiol as Potential Anticancer Drug
  
• 
  A Comparative Study on Cannabidiol-induced Apoptosis in Murine Thymocytes and El-4 Thymoma Cells
  
• 
  Cannabidiol-induced Apoptosis in Human Leukemia Cells: a Novel Role of Cannabidiol in the Regulation of P22phox and Nox4 Expression
  
• 
  Cannabidiol Inhibits Lung Cancer Cell Invasion and Metastasis Via Intercellular Adhesion Molecule-1
  
• 
  Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy, Safety, and Tolerability of Thc:CBD Extract and Thc Extract in Patients With Intractable Cancer-related Pain
  
• 
  Induction of Apoptosis by Cannabinoids in Prostate and Colon Cancer Cells Is Phosphatase Dependent
  
• 
  Anticancer Activity of Anandamide in Human Cutaneous Melanoma Cells

Notable Studies on Cannabidiol for Diabetes:

• 
  Cannabidiol Lowers Incidence of Diabetes in Non-obese Diabetic Mice
  
• Neuroprotective and Blood-retinal Barrier-preserving Effects of Cannabidiol in Experimental Diabetes
• 
  Cannabinoids Alter Endothelial Function in the Zucker Rat Model of Type 2 Diabetes
  
• 
  Cannabidiol Arrests Onset of Autoimmune Diabetes in NOD Mice
  
• Activation of the Peripheral Endocannabinoid System in Human Obesity
• 
  The Endocannabinoid System and Plant-derived Cannabinoids in Diabetes and Diabetic Complications
  
• 
  Cannabidiol Protects Retinal Neurons by Preserving Glutamine Synthetase Activity in Diabetes
  
• Regulation, Function, and Dysregulation of Endocannabinoids in Models of Adipose and β-Pancreatic Cells and in Obesity and Hyperglycemia
• Endocannabinoids and the Control of Energy Homeostasis
• 
  Cannabinoid Receptor 1 Blockade Ameliorates Albuminuria in Experimental Diabetic Nephropathy
  
• 
  Cannabinoids and Endocannabinoids in Metabolic Disorders with Focus on Diabetes
  
• 
  Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study
  
• 
  Biochemical and Immunohistochemical Changes in Delta-9-tetrahydrocannabinol-treated Type 2 Diabetic Rats
  
• 
  Cannabidiol Attenuates Cardiac Dysfunction, Oxidative Stress, Fibrosis, and Inflammatory and Cell Death Signaling Pathways in Diabetic Cardiomyopathy
  
• 
  Diabetic Retinopathy: Role of Inflammation and Potential Therapies for Anti-Inflammation
  
• 
  The Endocannabinoid System in Obesity and Type 2 Diabetes
  
• 
  Cannabinoid-mediated Modulation of Neuropathic Pain and Microglial Accumulation in a Model of Murine Type I Diabetic Peripheral Neuropathic Pain
  
• The Impact of Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults

Notable Studies on Cannabidiol for Epilepsy:

• 
  Cannabidiol: Antiepileptic Drug Comparisons and Interactions in Experimentally Induced Seizures in Rats
  
• 
  Report of a Parent Survey of Cannabidiol-enriched Cannabis Use in Pediatric Treatment-resistant Epilepsy
  
• 
  The Role of Potassium Bk Channels in Anticonvulsant Effect of Cannabidiol in Pentylenetetrazole and Maximal Electroshock Models of Seizure in Mice
  
• 
  Cannabidiol Exerts Anti-convulsant Effects in Animal Models of Temporal Lobe and Partial Seizures
  
• 
  Cannabidiol Displays Anti-epileptiform and Antiseizure Properties in Vitro and in Vivo
  
• 
  Report of a Parent Survey of Cannabidiol-enriched Cannabis Use in Pediatric Treatment-resistant Epilepsy
  
• 
  Cannabis, Cannabidiol, and Epilepsy: from Receptors to Clinical Response
  
• Nonpsychotropic Plant Cannabinoids, Cannabidivarin (CBDV) and Cannabidiol (CBD), Activate and Desensitize Transient Receptor Potential Vanilloid 1 (TRPV1) Channels in Vitro: Potential for the Treatment of Neuronal Hyperexcitability
• 
  Chronic Administration of Cannabidiol to Healthy Volunteers and Epileptic Patients
  
• 
  Could Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy?
  
• 
  Therapeutic Effects of Cannabinoids in Animal Models of Seizures, Epilepsy, Epileptogenesis, and Epilepsy-related Neuroprotection
  
• 
  Pharmacology of Cannabinoids in the Treatment of Epilepsy
  
• 
  Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure
  
• 
  The Cannabinoids as Potential Antiepileptics
  
• 
  Hypnotic and Antiepileptic Effects of Cannabidiol
  
• 
  Cannabidiol Exerts Anti-convulsant Effects in Animal Models of Temporal Lobe and Partial Seizures
  
• 
  Cannabidivarin (cbdv) Suppresses Pentylenetetrazole (ptz)-induced Increases in Epilepsy-related Gene Expression
  
• 
  Seizing an Opportunity for the Endocannabinoid System
  
• 
  Endocannabinoid System Protects Against Cryptogenic Seizures

Notable Studies on Cannabidiol for Nausea:

• 
  Cannabidiol, a Non-psychotropic Component of Cannabis, Attenuates Vomiting and Nausea-like Behaviour Via Indirect Agonism of 5-HT(1A) Somatodendritic Autoreceptors in the Dorsal Raphe Nucleus
  
• 
  Regulation of Nausea and Vomiting by Cannabinoids
  
• 
  The Effects of Cannabidiol and Tetrahydrocannabinol on Motion-induced Emesis in Suncus Murinus
  
• 
  Regulation of Nausea and Vomiting by Cannabinoids and the Endocannabinoid System
  
• 
  Preliminary Efficacy and Safety of an Oromucosal Standardized Cannabis Extract in Chemotherapy-induced Nausea and Vomiting
  
• 
  Suppression of Lithium Chloride-induced Conditioned Gaping (a Model of Nausea-induced Behaviour) in Rats (using the Taste Reactivity Test) With Metoclopramide Is Enhanced by Cannabidiolic Acid
  
• 
  The Prevalence and Incidence of Medicinal Cannabis on Prescription in the Netherlands
  
• 
  Interaction Between Non-psychotropic Cannabinoids in Marihuana: Effect of Cannabigerol (CBG) on the Anti-nausea or Anti-emetic Effects of Cannabidiol (CBD) in Rats and Shrews
  
• 
  Cannabidiol, a Non-psychoactive Component of Cannabis and Its Synthetic Dimethylheptyl Homolog Suppress Nausea in an Experimental Model With Rats
  
• 
  Effect of Combined Oral Doses of Δ(9)-tetrahydrocannabinol (THC) and Cannabidiolic Acid (CBDA) on Acute and Anticipatory Nausea in Rat Models
  
• 
  Cannabidiolic Acid Prevents Vomiting in Suncus Murinus and Nausea-induced Behaviour in Rats by Enhancing 5-HT1A Receptor Activation
  

Notable Studies on Cannabidiol for Nausea:

• 
  A Double-blind, Randomized, Placebo-controlled, Parallel-group Study of THC/CBD Oromucosal Spray in Combination With the Existing Treatment Regimen, in the Relief of Central Neuropathic Pain in Patients With Multiple Sclerosis
  
• 
  Cannabinoids in the Management of Difficult to Treat Pain
  
• 
  An Open-label Extension Study to Investigate the Long-term Safety and Tolerability of THC/CBD Oromucosal Spray and Oromucosal Thc Spray in Patients With Terminal Cancer-related Pain Refractory to Strong Opioid Analgesics
  
• 
  Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
  
• 
  Pain Relief with Cannabinoids: the Importance of Endocannabinoids and Cannabinoids for Therapy
  
• 
  Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients With Intractable Cancer-related Pain
  
• 
  Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats
  
• 
  Cannabidiol – Delta9-Tetrahydrocannabinol Interactions on Acute Pain and Locomotor Activity
  
• 
  Non-psychoactive Cannabinoids Modulate the Descending Pathway of Antinociception in Anaesthetized Rats Through Several Mechanisms of Action
  
• 
  Cannabinoids Suppress Inflammatory and Neuropathic Pain by Targeting Α3 Glycine Receptors
  
• 
  Meta-analysis of Cannabis Based Treatments for Neuropathic and Multiple Sclerosis-related Pain
  
• 
  Sativex: Clinical Efficacy and Tolerability in the Treatment of Symptoms of Multiple Sclerosis and Neuropathic Pain
  
• 
  Cannabinoids for Neuropathic Pain
  
• 
  Neuropathic Orofacial Pain: Cannabinoids as a Therapeutic Avenue
  
• 
  Oromucosal Delta9-tetrahydrocannabinol/cannabidiol for Neuropathic Pain Associated With Multiple Sclerosis: an Uncontrolled, Open-label, 2-year Extension Trial
  
• 
  The Non-psychoactive Cannabis Constituent Cannabidiol Is an Orally Effective Therapeutic Agent in Rat Chronic Inflammatory and Neuropathic Pain
  
• 
  Vanilloid TRPV1 Receptor Mediates The Antihyperalgesic Effect Of The Nonpsychoactive Cannabinoid, Cannabidiol, In A Rat Model Of Acute Inflammation
  
• 
  Cannabidiol Inhibits Paclitaxel-induced Neuropathic Pain Through 5-HT1A) Receptors Without Diminishing Nervous System Function or Chemotherapy Efficacy
  
• 
  Sativex Successfully Treats Neuropathic Pain Characterised by Allodynia: a Randomised, Double-blind, Placebo-controlled Clinical Trial
  
• 
  Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex, a Cannabis-based Medicine

Stay Up-to-Date with the Latest News About CBD

Sign up for our newsletter and you receive not only high-quality information, news, and educational materials, but as a loyal reader, you also gain access to occasional discounts on our recommended CBD products.

Current CBD Clinical Trials